CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
October 11 2023 - 8:30AM
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused
on developing and commercializing therapeutic products for the
prevention and treatment of life-threatening conditions and
diseases, today announced that an abstract has been accepted for
presentation at the IDWeek 2023 meeting being held in Boston,
Massachusetts, October 11 – 15.
The abstract being presented highlights data
regarding in vitro activity of taurolidine against the fungus
Candida auris, an emerging cause of life-threatening bloodstream
infections, with increasing resistance to common antifungal agents.
Taurolidine exhibited in vitro antimicrobial activity against all
C. auris strains and isolates regardless of geographic source, year
of isolation, or clade. There was no evidence that taurolidine
activity was affected by resistance to amphotericin B or
fluconazole. Based on the in vitro data, catheter lock solutions
containing the broad-spectrum antimicrobial taurolidine have the
potential to prevent catheter related bloodstream infections
(CRBSI) caused by C. auris, including clinical isolates that are
resistant to common antifungals.
The abstract is available through the IDWeek
conference website.
IDWeek 2023 Conference Abstract:
In Vitro Antimicrobial Activity of
Taurolidine against Candida auris
Bloodstream Isolates from Global SourcesPoster
#2117Antony Pfaffle1, Leonard Duncan2, Mariana Castanheira2, Bruce
Reidenberg3, Cecilia Carvalhaes2, Jessica Vaughn1 and Phoebe
Mounts11CorMedix Inc.; 2JMI Laboratories; 3Weill Cornell
Medicine
About CorMedix
CorMedix Inc. is a biopharmaceutical company
focused on developing and commercializing therapeutic products for
the prevention and treatment of life-threatening conditions and
diseases. The Company is focused on developing its lead product
DefenCath®, a novel, non-antibiotic antimicrobial solution designed
to prevent costly and life-threatening bloodstream infections
associated with the use of central venous catheters in patients
undergoing chronic hemodialysis. DefenCath has been designated by
FDA as Fast Track and as a Qualified Infectious Disease Product
(QIDP), and the original New Drug Application (NDA) received
priority review in recognition of its potential to address an unmet
medical need. QIDP provides for an additional five years of
marketing exclusivity, which will be added to the five years
granted to a New Chemical Entity upon approval of the NDA. CorMedix
also committed to conducting a clinical study in pediatric patients
using a central venous catheter for hemodialysis when the NDA is
approved, which will add an additional six months of marketing
exclusivity when the study is completed. CorMedix received a second
Complete Response Letter from the FDA last August related to
deficiencies at both its primary contract manufacturer and its
supplier of heparin API. After receiving guidance from FDA at a
Type A meeting in April of 2023, the NDA for DefenCath was
resubmitted and accepted for filing with a target action date in
November. CorMedix also intends to develop DefenCath as a catheter
lock solution for use in other patient populations, and the Company
is working with top-tier researchers to develop taurolidine-based
therapies for rare pediatric cancers. For more information visit:
www.cormedix.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that are subject to risks and uncertainties. All
statements, other than statements of historical facts, regarding
management’s expectations, beliefs, goals, plans or CorMedix’s
prospects, including, but not limited to, CorMedix’s future
financial position, financing plans, future revenues, projected
costs and the sufficiency of our cash and short-term investments to
fund our operations should be considered forward-looking
statements. Readers are cautioned that actual results may differ
materially from projections or estimates due to a variety of
important factors, including: the risks and uncertainties related
to market conditions; the ability to secure final FDA approval
prior to July 1, 2024; CorMedix’s ability to manage its cash
resources and the impact on current, planned or future research;
the ability to achieve commercial preparedness ahead of the target
action date in November 2023; and that preclinical results are not
indicative of success in clinical trials and might not be
replicated in any subsequent studies or trials. These and other
risks are described in greater detail in CorMedix’s filings with
the SEC, copies of which are available free of charge at the SEC’s
website at www.sec.gov or upon request from CorMedix. CorMedix may
not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. CorMedix assumes no obligation and
does not intend to update these forward-looking statements, except
as required by law.
Investor Contact:Dan
FerryManaging DirectorLifeSci Advisors(617) 430-7576
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CorMedix (NASDAQ:CRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024